CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
Recruiting · NCT05948033 · Registry updated 2023-07-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2023-07-17 | NCT05948033 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chinese PLA General Hospital | 238 |
| UTC Therapeutics Inc. | 8 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| China | Beijing | China | 4 |